Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Green Cross Health Limited (GXH.NZ)
Auckland, AUK, NZ
Green Cross Health Limited provides health care and advice services to communities in New Zealand. It operates through Pharmacy Services and Medical Services segments. The Pharmacy Services segment offers pharmacy services through stores, equity accounted investments, and franchise stores. It operates community pharmacies under the Unichem and Life Pharmacy brands. The Medical Services segment operates owned and equity accounted medical centres, and offers support services provided to its medical centres, as well as medical centres outside the company. It also provides back office and operational services to medical centres; and offers family healthcare services through GP, accident, and medical centres under The Doctors brand. Green Cross Health Limited was incorporated in 1999 and is based in Auckland, New Zealand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.53% | +8.70% | +7.91% | +23.97% | +38.89% | +42.86% | +85.19% | +3.45% | +40.19% | -47.37% | -70.87% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+4.0% Q1'26: +10.4% (vs Q1'24)
-
EPS growth Medical - Care Facilities: +19.2%+27.3% ★ Q1'26: +104.2% (vs Q1'24)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+5.4% Q1'26: +10.2% (vs Q1'24)
-
EBIT margin Medical - Care Facilities: +11.3%+7.1% Q1'26: +8.8% (vs Q1'24)
-
ROIC Medical - Care Facilities: +6.8%+9.8% ★ Q1'26: +25.0% (vs Q1'24)
-
Share dilution Medical - Care Facilities: +0.0%+0.1% Q1'26: +0.5% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×2.11× Q1'26: 0.88× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2019 actual |
Mar 2020 actual |
|---|---|---|
| Revenue |
567.24M
est: 568.03M (-0.1%)
|
568.53M
est: 605.55M (-6.1%)
|
| EBITDA |
37.85M
est: 57.49M (-34.2%)
|
54.08M
est: 61.29M (-11.8%)
|
| EBIT |
29.42M
est: 34.91M (-15.7%)
|
25.43M
est: 37.21M (-31.7%)
|
| Net Income |
16.11M
|
13.49M
|
| SGA |
285.25M
est: 210.07M (+35.8%)
|
265.31M
est: 223.94M (+18.5%)
|
| EPS |
0.11
|
0.09
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ben Doshi | Group Chief Financial Officer & Company Secretary | — | male |
| Grant Clayton Bai | Chief Executive Officer of Pharmacy & Medical | — | male |
| Mark Smith | Chief Information Officer | — | male |
| Rachael Newfield | Group Chief Executive Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GXH.NZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
